JP2004290129A - Common salt-containing food or beverage - Google Patents
Common salt-containing food or beverage Download PDFInfo
- Publication number
- JP2004290129A JP2004290129A JP2003089773A JP2003089773A JP2004290129A JP 2004290129 A JP2004290129 A JP 2004290129A JP 2003089773 A JP2003089773 A JP 2003089773A JP 2003089773 A JP2003089773 A JP 2003089773A JP 2004290129 A JP2004290129 A JP 2004290129A
- Authority
- JP
- Japan
- Prior art keywords
- salt
- containing food
- substance
- blood pressure
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000002639 sodium chloride Nutrition 0.000 title claims abstract description 69
- 235000013305 food Nutrition 0.000 title claims abstract description 53
- 235000013361 beverage Nutrition 0.000 title claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 title abstract description 24
- 239000011780 sodium chloride Substances 0.000 title abstract description 16
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 42
- 239000000126 substance Substances 0.000 claims abstract description 37
- 230000036772 blood pressure Effects 0.000 claims abstract description 21
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 21
- 239000001103 potassium chloride Substances 0.000 claims abstract description 21
- 235000013555 soy sauce Nutrition 0.000 claims abstract description 14
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 244000294411 Mirabilis expansa Species 0.000 claims abstract description 10
- 235000015429 Mirabilis expansa Nutrition 0.000 claims abstract description 10
- 235000013536 miso Nutrition 0.000 claims abstract description 10
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 230000001737 promoting effect Effects 0.000 claims abstract description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims abstract description 4
- 239000002934 diuretic Substances 0.000 claims abstract description 4
- 230000002889 sympathetic effect Effects 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims description 66
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical group NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 17
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 10
- 235000008696 isoflavones Nutrition 0.000 claims description 10
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 8
- KRGPXXHMOXVMMM-CIUDSAMLSA-N (S,S,S)-nicotianamine Chemical group [O-]C(=O)[C@@H]([NH3+])CC[NH2+][C@H](C([O-])=O)CC[NH+]1CC[C@H]1C([O-])=O KRGPXXHMOXVMMM-CIUDSAMLSA-N 0.000 claims description 7
- KRGPXXHMOXVMMM-UHFFFAOYSA-N nicotianamine Natural products OC(=O)C(N)CCNC(C(O)=O)CCN1CCC1C(O)=O KRGPXXHMOXVMMM-UHFFFAOYSA-N 0.000 claims description 7
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical group C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 6
- 229940124549 vasodilator Drugs 0.000 claims description 6
- 230000001077 hypotensive effect Effects 0.000 claims description 3
- 108010064733 Angiotensins Proteins 0.000 claims description 2
- 102000015427 Angiotensins Human genes 0.000 claims description 2
- 108090000783 Renin Proteins 0.000 claims description 2
- 102100028255 Renin Human genes 0.000 claims description 2
- 230000036454 renin-angiotensin system Effects 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract description 11
- 208000006029 Cardiomegaly Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 6
- 230000001882 diuretic effect Effects 0.000 abstract description 3
- 230000002541 vasodepressive effect Effects 0.000 abstract 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract 1
- 244000046052 Phaseolus vulgaris Species 0.000 abstract 1
- 235000021067 refined food Nutrition 0.000 abstract 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- -1 isoflavone compound Chemical class 0.000 description 8
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 6
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 6
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 6
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 6
- 229960003147 reserpine Drugs 0.000 description 6
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 6
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 5
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 5
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 229960002003 hydrochlorothiazide Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 description 2
- 229960005384 hydralazine hydrochloride Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000013622 meat product Nutrition 0.000 description 2
- 229960002289 nicardipine hydrochloride Drugs 0.000 description 2
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 235000021018 plums Nutrition 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- RZPZLFIUFMNCLY-WLHGVMLRSA-N (e)-but-2-enedioic acid;1-(propan-2-ylamino)-3-[4-(2-propan-2-yloxyethoxymethyl)phenoxy]propan-2-ol Chemical compound OC(=O)\C=C\C(O)=O.CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 RZPZLFIUFMNCLY-WLHGVMLRSA-N 0.000 description 1
- AKHXXQAIVSMYIS-UHFFFAOYSA-N 1,1-dioxo-3-pentyl-6-(trifluoromethyl)-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound FC(F)(F)C1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CCCCC)NC2=C1 AKHXXQAIVSMYIS-UHFFFAOYSA-N 0.000 description 1
- ITZWQFLTSRCDPC-UHFFFAOYSA-N 1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol;hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)COC1=CC=CC=C1C1CCCC1 ITZWQFLTSRCDPC-UHFFFAOYSA-N 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- XEMPUKIZUCIZEY-YSCHMLPRSA-N Barnidipine hydrochloride Chemical compound Cl.C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 XEMPUKIZUCIZEY-YSCHMLPRSA-N 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- QLTVVOATEHFXLT-UHFFFAOYSA-N Cadralazine Chemical compound CCOC(=O)NNC1=CC=C(N(CC)CC(C)O)N=N1 QLTVVOATEHFXLT-UHFFFAOYSA-N 0.000 description 1
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RBBWCVQDXDFISW-UHFFFAOYSA-N Feprazone Chemical compound O=C1C(CC=C(C)C)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 RBBWCVQDXDFISW-UHFFFAOYSA-N 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- DGFYECXYGUIODH-UHFFFAOYSA-N Guanfacine hydrochloride Chemical compound Cl.NC(N)=NC(=O)CC1=C(Cl)C=CC=C1Cl DGFYECXYGUIODH-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Hypadil (TN) Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- WQVZLXWQESQGIF-UHFFFAOYSA-N Labetalol hydrochloride Chemical compound Cl.C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 WQVZLXWQESQGIF-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FNQQBFNIYODEMB-UHFFFAOYSA-N Meticrane Chemical compound C1CCS(=O)(=O)C2=C1C=C(C)C(S(N)(=O)=O)=C2 FNQQBFNIYODEMB-UHFFFAOYSA-N 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000219 Sympatholytic Substances 0.000 description 1
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 description 1
- SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 1
- 229960003830 acebutolol hydrochloride Drugs 0.000 description 1
- KTUFKADDDORSSI-UHFFFAOYSA-N acebutolol hydrochloride Chemical compound Cl.CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 KTUFKADDDORSSI-UHFFFAOYSA-N 0.000 description 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 229950010351 amosulalol Drugs 0.000 description 1
- LVEXHFZHOIWIIP-UHFFFAOYSA-N amosulalol Chemical compound COC1=CC=CC=C1OCCNCC(O)C1=CC=C(C)C(S(N)(=O)=O)=C1 LVEXHFZHOIWIIP-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229950010731 arotinolol Drugs 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960003619 benazepril hydrochloride Drugs 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- IUGQFMIATSVYLK-UHFFFAOYSA-N benzyl 2-(4-hydroxyphenyl)acetate Chemical compound C1=CC(O)=CC=C1CC(=O)OCC1=CC=CC=C1 IUGQFMIATSVYLK-UHFFFAOYSA-N 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960005400 bisoprolol fumarate Drugs 0.000 description 1
- 229960001035 bopindolol Drugs 0.000 description 1
- DQGFCLJXYFXXIJ-LFIBNONCSA-N budralazine Chemical compound C1=CC=C2C(N/N=C(C)/C=C(C)C)=NN=CC2=C1 DQGFCLJXYFXXIJ-LFIBNONCSA-N 0.000 description 1
- 229950001730 budralazine Drugs 0.000 description 1
- 229960003612 bunazosin hydrochloride Drugs 0.000 description 1
- 229960005211 cadralazine Drugs 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 description 1
- 229960002631 carbazochrome Drugs 0.000 description 1
- FYBXRCFPOTXTJF-UHFFFAOYSA-N carteolol hydrochloride Chemical compound [Cl-].N1C(=O)CCC2=C1C=CC=C2OCC(O)C[NH2+]C(C)(C)C FYBXRCFPOTXTJF-UHFFFAOYSA-N 0.000 description 1
- 229960002165 carteolol hydrochloride Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960000220 doxazosin mesylate Drugs 0.000 description 1
- VJECBOKJABCYMF-UHFFFAOYSA-N doxazosin mesylate Chemical compound [H+].CS([O-])(=O)=O.C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 VJECBOKJABCYMF-UHFFFAOYSA-N 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960000489 feprazone Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- YUFWAVFNITUSHI-UHFFFAOYSA-N guanethidine monosulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.NC(=N)NCCN1CCCCCCC1 YUFWAVFNITUSHI-UHFFFAOYSA-N 0.000 description 1
- 229960004848 guanethidine sulfate Drugs 0.000 description 1
- 229960004746 guanfacine hydrochloride Drugs 0.000 description 1
- 229960003313 hydroflumethiazide Drugs 0.000 description 1
- DMDGGSIALPNSEE-UHFFFAOYSA-N hydroflumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O DMDGGSIALPNSEE-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 description 1
- 229960003409 imidapril hydrochloride Drugs 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 229960003091 labetalol hydrochloride Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960003738 meticrane Drugs 0.000 description 1
- 229960001300 metoprolol tartrate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229950000754 nipradilol Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229950001707 penflutizide Drugs 0.000 description 1
- 229960003929 perindopril erbumine Drugs 0.000 description 1
- IYNMDWMQHSMDDE-MHXJNQAMSA-N perindopril erbumine Chemical compound CC(C)(C)N.C1CCC[C@@H]2N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H](C(O)=O)C[C@@H]21 IYNMDWMQHSMDDE-MHXJNQAMSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002386 prazosin hydrochloride Drugs 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 229960003042 quinapril hydrochloride Drugs 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 229950006534 syrosingopine Drugs 0.000 description 1
- 229960004084 temocapril Drugs 0.000 description 1
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001909 terazosin hydrochloride Drugs 0.000 description 1
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229950008411 tilisolol Drugs 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- UHLOVGKIEARANS-QZHINBJYSA-N tripamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN2C[C@@H]3[C@H]4CC[C@H](C4)[C@@H]3C2)=C1 UHLOVGKIEARANS-QZHINBJYSA-N 0.000 description 1
- 229950004678 tripamide Drugs 0.000 description 1
- 229960001130 urapidil Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/50—Soya sauce
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Soy Sauces And Products Related Thereto (AREA)
- Seasonings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【０００１】
【発明の属する技術分野】
本発明は、食塩含有飲食品を摂取した場合に、血圧の上昇を抑制し、さらに心臓肥大を予防できる食塩含有飲食品に関する。
【０００２】
【従来の技術】
高血圧による心臓肥大が慢性化すると、心筋梗塞、心不全、狭心症などの虚血性心疾患を招来するので、心臓肥大を予防することは極めて意義深い。
従来、食塩含有飲食品を摂取した場合に、血圧の上昇を抑制できる食塩含有飲食品が知られている。例えば、カゼインを蛋白質分解酵素により分解して得られるアンジオテンシン転換酵素を阻害するペプチドを含有することを特徴とするナトリウム塩含有経口摂食組成物が知られている（特許文献１参照。）。
また、みそに０．０１〜０．５％（Ｗ／Ｗ）のイソフラボン化合物を添加してなるイソフラボン化合物高含有みそ（食塩含有食品）が知られている（特許文献２参照。）。なおイソフラボン化合物は血圧降下作用を有する物質（一酸化窒素産生促進物質）として利用できることが知られている（技術文献１参照。）。
【０００３】
【特許文献１】
特開平２−１６７０５２号公報
【０００４】
【特許文献２】
特開平９−１８７２４４号公報
【０００５】
【技術文献１】
第５５回日本栄養・食糧学会大会講演要旨集、第２０８頁、３Ｈ−０４ａ
【０００６】
しかしながら、これら２つの食塩含有飲食品は、摂取すると、食塩摂取にも拘わらず、血圧降下作用を有する物質の存在により血圧の上昇を抑制できるが、心臓肥大を予防できないことが判明した。
【０００７】
【発明が解決しようとする課題】
本発明は、食塩含有飲食品を摂取したとき、血圧の上昇を抑制し、しかも心臓肥大を予防できる食塩含有飲食品を得ることを目的とする。
【０００８】
【課題を解決するための手段】
本発明者らは、上記課題を解決するため鋭意検討を重ねた結果、血圧降下作用を有する物質を含有する食塩含有飲食品に塩化カリウムを共存させるときは、上記課題を解決できることを知り、この知見に基づいて本発明を完成した。
【０００９】
すなわち、本発明は、血圧降下作用を有する物質と塩化カリウムとを含有してなる食塩含有飲食品である。
【００１０】
【発明の実施の形態】
以下、本発明を詳細に説明する。
【００１１】
本発明において用いられる血圧降下作用を有する物質としては、レニン・アンジオテンシン系抑制物質、交換神経抑制物質、一酸化窒素産生促進物質、利尿物質、カルシウム拮抗物質に属する血管拡張物質、その他に属する血管拡張物質、その他の血圧降下作用を有する物質などが挙げられる。
これらは、単独で、あるいは併用して用いてもよい。
【００１２】
またレニン・アンジオテンシン系抑制物質としては、ニコチアナミン（特開平５−２４６８６５号参照）、海苔由来ペプチド（特許第３２７２６２１）、魚由来ペプチド（特開２００２−２４１３０５）、ラクトトリペプチド（特許第３０２８４１１）、アセラプリル、塩酸イミダプリル、マレイン酸エナラプリル、カプトプリル、塩酸キナプリル、シラザプリル、塩酸テモカプリル、塩酸デラプリル、トランドラプリル、塩酸ベナゼプリル、ペリンドプリルエルブミン、リシノプリル、カンデサルタンシレキセチル、ロサルタンカリウムなどが挙げられる。
【００１３】
また上記交換神経抑制物質としては、γ−アミノ酪酸（特開平１１−１５１０７２号参照）、ナドロール、塩酸プロプラノロール、塩酸チリソロール、ニプラジロール、塩酸インデノロール、塩酸カルテオロール、ピンドロール、塩酸ペンブトロール、塩酸プニトロロール、マロン酸ボピンドロール、アテノロール、フマル酸ビソプロロール、酒石酸メトプロロール、塩酸ベタキソロール、塩酸アセブトロール、塩酸セリプロロール、塩酸アモスラロール、塩酸アロチノロール、カルベジロール、塩酸ラベタロール、塩酸ベバントロール、メチルドバ、硫酸グアネチジン、硫酸ベタニジンなどが挙げられる。
【００１４】
また一酸化窒素産生促進物質としては、イソフラボン（特開平９−１８７２４４号参照）などが挙げられる。
【００１５】
また利尿物質としては、トリパミド、メチクラン、メトラゾン、メフルシド、フロセミド、ウラピジル、塩酸テラゾシン、メシル酸ドキサゾシン、塩酸ブナゾシン、塩酸プラゾシン、酢酸グアナベンズ、塩酸グアンファシン、ヒドロクロロチアジド、ヒドロフルメチアジド、ベンチルヒドロクロロチアジド、ペンフルチジド、メチクロチアジド、インダパミド、クロルタリドン、スピロノラクトン、トリアムテレンなどが挙げられる。
【００１６】
また血管拡張物質としては、（１）カルシウム拮抗物質に属するベシル酸アムロジピン、アラニジピン、塩酸エホニジピン、塩酸ジルチアゼム、塩酸ニカルジピン、シルニジピン、塩酸ニカルジピン、ニソルジピン、ニトレンジピン、ニフェジピン、ニルバジピン、塩酸バルニジピン、フェロジピン、塩酸ベニジピン、塩酸マニジピンなどが、また（２）その他に属する血管拡張物質として、カドララジン、塩酸トドララジン、塩酸ヒドララジン、ブドララジン、カリジノゲナーゼなどが挙げられる。
【００１７】
またその他の血圧降下作用を有する物質としては、アルサーオキシロン、シロシンゴピン、レセルピン、塩酸レセルピリン酸ジメチルアミノエチル、レシナミソ、メシル酸ジヒドロエルゴトキシン、レセルピン・カルバゾクロム・ベンチルヒドロクロロチアジド、レセルピン・塩酸ヒドララジン、レセルピン・塩酸ヒドララジン・ヒドロクロロチアジド、レセルピン・ヒドロクロロチアジド、フロセミド・レセルピンなどが挙げられる。
本発明では、この他血圧降下作用を有することが知られている任意を血圧降下作用を有する物質が採用可能である。
【００１８】
塩化カリウムとしては、通常の塩化カリウム、または塩化カリウム高濃度含有海水塩などが挙げられる。
【００１９】
食塩含有飲食品としては、食塩、味噌、醤油またはこれらを用いて加工された食品〔例えば食塩含有液状調味料（焼肉のたれ、ぽん酢醤油、ソースなど）、梅干し、漬物（浅漬、たくあんなど）、嗜好品（干物）、塩辛、乳製品（バターなど）、マヨネーズ、畜肉練製品（ソーセージなど）、菓子、ナッツおよびスポーツ飲料など〕が挙げられる。
【００２０】
本発明の食塩含有飲食品の製造は、通常の食塩含有飲食品の製造法を採用することができる。
【００２１】
本発明の食塩含有飲食品の製造において、食塩含有飲食品に対する血圧降下作用を有する物質の含有量は、摂取する該食塩含有飲食品の食塩換算で１ｇ当り、２ｍｇ〜２ｇとなるように調整することが好ましい。そのうち５〜５００ｍｇがより好ましく、１０〜１００ｍｇが最も好ましい。
【００２２】
食塩含有飲食品の製造において、食塩含有飲食品に対する血圧降下作用を有する物質の含有量の調整は、該物質を添加してもよいが、当該食塩含有食品の製造工程において、（１）優良微生物（麹菌、酵母、乳酸菌、その他優良バクテリアなど）を関与させ、該微生物により発酵、熟成などの手段により、または（２）各種酵素（ペプチダーゼ、プロテアーゼなど）による酵素分解の手段により、モロミなどの半製品中に血圧降下作用を有する物質を生成蓄積させてもよい。
【００２３】
また食塩含有飲食品に対する塩化カリウムの含有量は、摂取する該食塩含有飲食品の食塩換算で１ｇ当り、５０ｍｇ〜２ｇが挙げられるが、そのうち１００ｍｇ〜１ｇがより好ましい。
【００２４】
このようにして、本発明によれば食塩摂取にも拘わらず、血圧の上昇を抑制し、さらに心臓肥大を抑制できる食塩含有飲食品、例えば食塩、味噌、醤油またはこれらを用いて加工された食塩含有液状調味料（焼肉のたれ、ぽん酢醤油、ソースなど）、梅干し、漬物（浅漬、たくあんなど）、嗜好品（干物など）、塩辛、乳製品（バターなど）、マヨネーズ、畜肉練製品（ソーセージなど）、菓子、ナッツおよびスポーツ飲料などを得ることができる。
【００２５】
以下実験例を示して本発明の効果を具体的に説明する。
実験例１
【００２６】
実験例１
（高血圧性心肥大抑制効果確認のための実験例）
５週齢、自然発症高血圧ラット（以下、ＳＨＲラット）４８匹を６匹づつ以下の８群に分け試験を行った。
第１群（対照区）には、６％（Ｗ／Ｗ、以下％は特に断り無い限りＷ／Ｗによる）食塩（ＮａＣｌ）添加飼料（オリエンタル酵母工業社製、マウス・ラット飼育用飼料・「ＭＦ粉末飼料」に６％の割合で食塩を添加）を与えた。
第２群（比較例１区）には６％食塩（ＮａＣｌ）添加飼料に更に１％の割合でＫＣｌを添加した飼料を与えた。
第３群（比較例２区）には、６％食塩（ＮａＣｌ）添加飼料に更に０．１％の割合でニコチアナミン（以下ＮＦと略記する）を添加した飼料を与えた。
第４群（比較例３区）には、６％食塩（ＮａＣｌ）添加飼料に更に０．２％の割合でイソフラボンアグリコン（以下ＩＦと略記する）を添加した飼料を与えた。
第５群（比較例４区）には、６％食塩（ＮａＣｌ）添加飼料に更に０．１％の割合でγ−アミノ酪酸（以下ＧＡＢＡと略記する）を添加した飼料を与えた。
第６群（本発明１区）には、６％食塩（ＮａＣｌ）添加飼料に、１％の割合でＫＣｌ及び０．１％の割合でニコチアナミンを添加した資料を与えた。
第７群（本発明２区）には、６％食塩（ＮａＣｌ）添加飼料に、１％の割合でＫＣｌ及び０．２％の割合でイソフラボンアグリコンを添加した資料を与えた。
第８群（本発明３区）には、６％食塩（ＮａＣｌ）添加飼料に、１％の割合でＫＣｌ及び０．２％の割合でγ−アミノ酪酸を添加した資料を与えた。
３週間の試験期間終了時にラットの体重を測定し、その後ネンブタールで麻酔、放血殺した後、心臓を摘出しその湿重量を測定、体重１００ｇ当たりの心臓重量を算出した。また、比較例１区の体重１００ｇ当たりの心臓重量を１００とした場合の相対値を算出した。これらの結果を、表１に示す。
【００２７】
表１の結果から、血圧降下作用を有する物質（ニコチアナミン）を添加した食塩含有食品投与区（比較例２）、血圧降下作用を有する物質（イソフラボンアグリコン）を添加した食塩含有食品投与区（比較例３）および血圧降下作用を有する物質（γ−アミノ酪酸）を添加した食塩含有食品投与区（比較例３）は、血圧降下作用を有する物質を含まない食塩含有食品投与区（対照区）に比べて、心臓湿重量が殆ど変わらないことから、これらの血圧降下作用を有する物質は、食塩含有食品に添加した場合、該血圧降下作用を有する物質の存在により血圧の上昇の抑制効果を期待することは可能であっても、心臓肥大を抑制する効果は期待できないことが判る。
これに対し、血圧降下作用を有する物質（ニコチアナミン）と塩化カリウムを併用添加した食塩含有食品投与区（本発明１）、血圧降下作用を有する物質（イソフラボンアグリコン）と塩化カリウムを併用添加した食塩含有食品投与区（本発明２）および血圧降下作用を有する物質（γ−アミノ酪酸）と塩化カリウムを併用添加した食塩含有食品投与区（本発明３）は、血圧降下作用を有する物質を含まない食塩含有食品投与区（対照区）または、塩化カリウムを添加した食塩含有食品投与区（比較例１）に比べて、心臓湿重量が５〜７％減少することが判明した。このことから、本発明によれば、血圧の上昇を抑制し、しかも心臓肥大を予防できる食塩含有食品を得ることが判る。
【００２８】
【実施例】
以下実施例を示して本発明をより具体的に説明する。
【００３０】
実施例１
（塩味組成物）
食塩６０ｇ、塩化カリウム３０ｇおよびγ−アミノ酪酸１０ｇを均一に混和して本発明の塩味組成物を得た。
【００３１】
実施例２
（醤油）
通常の醤油の製造法に従い得られた火入醤油（食塩１５％Ｗ／Ｗ）１００ｍｌにニコチアナミン１．７ｇおよび塩化カリウム１．５ｇを添加溶解して本発明の醤油を得た。
【００３２】
実施例３
（醤油）
通常の醤油の製造法に従い得られた火入醤油（食塩１５％Ｗ／Ｗ）１００ｍｌにイソフラボンアグリコン３．４ｇおよび塩化カリウム１．５ｇを添加溶解して本発明の醤油を得た。
【００３３】
実施例４
（味噌）
通常の味噌の製造法に従い得られた赤味噌（食塩１１％Ｗ／Ｗ）１００ｇにγ−アミノ酪酸３．４ｇおよび塩化カリウム１．２ｇを添加溶解して本発明の味噌を得た。
【００３４】
【発明の効果】
本発明によれば、食塩含有飲食品を摂取したとき、血圧の上昇を抑制し、しかも心臓肥大を予防できる食塩含有飲食品を得ることができる。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a salt-containing food or beverage that can suppress an increase in blood pressure and prevent cardiac hypertrophy when ingesting the salt-containing food or beverage.
[0002]
[Prior art]
Chronic cardiac hypertrophy due to hypertension leads to ischemic heart disease such as myocardial infarction, heart failure, and angina, so preventing cardiac hypertrophy is extremely significant.
BACKGROUND ART Conventionally, salt-containing foods and drinks that can suppress an increase in blood pressure when salt-containing foods and drinks are ingested are known. For example, a sodium salt-containing oral feeding composition characterized by containing a peptide that inhibits angiotensin converting enzyme obtained by decomposing casein with a protease is known (see Patent Document 1).
Also, there is known an isoflavone compound-rich miso (salt-containing food) obtained by adding 0.01 to 0.5% (W / W) of an isoflavone compound to miso (see Patent Document 2). It is known that an isoflavone compound can be used as a substance having a blood pressure lowering action (nitrogen oxide production promoting substance) (see Technical Document 1).
[0003]
[Patent Document 1]
Japanese Unexamined Patent Publication No. Hei 2-167052
[Patent Document 2]
JP-A-9-187244 [0005]
[Technical Document 1]
Proceedings of the 55th Annual Meeting of the Japan Society of Nutrition and Food Science, page 208, 3H-04a
[0006]
However, it has been found that, when these two salt-containing foods and drinks are ingested, the increase in blood pressure can be suppressed due to the presence of a substance having a blood pressure lowering effect, but cardiac hypertrophy cannot be prevented, despite the intake of salt.
[0007]
[Problems to be solved by the invention]
An object of the present invention is to provide a salt-containing food or drink that suppresses a rise in blood pressure and prevents cardiac hypertrophy when the salt-containing food or drink is ingested.
[0008]
[Means for Solving the Problems]
The present inventors have conducted intensive studies to solve the above problems, and found that when potassium chloride is allowed to coexist in a salt-containing food or drink containing a substance having a hypotensive effect, the above problems can be solved. The present invention has been completed based on the findings.
[0009]
That is, the present invention is a salt-containing food or drink comprising a substance having a hypotensive effect and potassium chloride.
[0010]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
[0011]
Examples of the substance having a blood pressure lowering effect used in the present invention include a renin / angiotensin system inhibitor, a sympathetic inhibitor, a nitric oxide production promoter, a diuretic, a vasodilator belonging to calcium antagonist, and a vasodilator belonging to other Substances, other substances having a blood pressure lowering effect, and the like.
These may be used alone or in combination.
[0012]
Examples of the renin-angiotensin system inhibitor include nicotianamine (see JP-A-5-246865), a laver-derived peptide (Japanese Patent No. 3272621), a fish-derived peptide (JP-A-2002-241305), a lactotripeptide (Japanese Patent No. 3028411), Examples include acerapril, imidapril hydrochloride, enalapril maleate, captopril, quinapril hydrochloride, cilazapril, temocapril hydrochloride, delapril hydrochloride, trandolapril, benazepril hydrochloride, perindopril erbumine, lisinopril, candesartan cilexetil, and losartan potassium.
[0013]
Examples of the above-mentioned sympatholytic substances include γ-aminobutyric acid (see JP-A-11-152072), nadolol, propranolol hydrochloride, tilisolol hydrochloride, nipradilol, indenolol hydrochloride, carteolol hydrochloride, pindolol, penbutolol hydrochloride, pnitrolol hydrochloride, malonic acid, and malonic acid. Examples include bopindolol, atenolol, bisoprolol fumarate, metoprolol tartrate, betaxolol hydrochloride, acebutolol hydrochloride, ceriprolol hydrochloride, amosulalol hydrochloride, arotinolol hydrochloride, carvedilol, labetalol hydrochloride, bevantrol hydrochloride, methyldoba, guanethidine sulfate, betatanidine sulfate and the like.
[0014]
Examples of the nitric oxide production promoting substance include isoflavones (see JP-A-9-187244).
[0015]
Examples of the diuretic include tripamide, meticran, metrazone, mefluside, furosemide, urapidil, terazosin hydrochloride, doxazosin mesylate, bunazosin hydrochloride, prazosin hydrochloride, guanabenz acetate, guanfacine hydrochloride, hydrochlorothiazide, hydroflumethiazide, ventilhydrochlorothiazide, penflutizide, and methiclozide. Thiazide, indapamide, chlorthalidone, spironolactone, triamterene and the like.
[0016]
Examples of the vasodilator include (1) amlodipine besylate, alanidipine, efonidipine hydrochloride, which belong to a calcium antagonist, diltiazem hydrochloride, nicardipine hydrochloride, cilnidipine, nicardipine hydrochloride, nisoldipine, nitrendipine, nifedipine, nilvadipine, barnidipine hydrochloride, felodipine, and benidipine hydrochloride. Vasodilators belonging to (2) Others include cadralazine, todralazine hydrochloride, hydralazine hydrochloride, budralazine, caridinogenase and the like.
[0017]
Other substances having an antihypertensive effect include arteroxylone, syrosingopine, reserpine, dimethylaminoethyl reserpyrate hydrochloride, recinamiso, dihydroergotoxin mesylate, reserpine carbazochrome bentylhydrochlorothiazide, reserpine hydrochlorazine hydrazine, reserpine And hydralazine hydrochloride hydrochlorothiazide, reserpine hydrochlorothiazide, furosemide reserpine and the like.
In the present invention, any substance known to have a blood pressure lowering effect can be employed.
[0018]
Examples of the potassium chloride include ordinary potassium chloride and sea salt containing potassium chloride at a high concentration.
[0019]
Examples of salt-containing foods and drinks include salt, miso, soy sauce or food processed using these (eg, salt-containing liquid seasonings (such as grilled meat sauce, ponzu soy sauce, sauce, etc.), dried plums, pickles (such as pickled vegetables, takuan, etc.), Luxury goods (dried), salted food, dairy products (such as butter), mayonnaise, meat and meat products (such as sausage), confectionery, nuts, sports drinks and the like).
[0020]
For the production of the salt-containing food and drink of the present invention, the usual method for producing salt-containing food and drink can be adopted.
[0021]
In the production of the salt-containing food or drink of the present invention, the content of the substance having a blood pressure lowering effect on the salt-containing food or drink is adjusted to be 2 mg to 2 g per 1 g of the salt-containing food or drink to be ingested. Is preferred. Of these, 5 to 500 mg is more preferred, and 10 to 100 mg is most preferred.
[0022]
In the production of the salt-containing food or drink, the content of the substance having a blood pressure lowering effect on the salt-containing food or drink may be adjusted by adding the substance. (Koji molds, yeasts, lactic acid bacteria, other excellent bacteria, etc.), and the fermentation and ripening of the microorganisms, or (2) the enzymatic decomposition by various enzymes (peptidases, proteases, etc.). A substance having a blood pressure lowering effect may be produced and accumulated in the product.
[0023]
The content of potassium chloride in the salt-containing food or drink is 50 mg to 2 g per 1 g of salt in the salt-containing food or drink to be ingested, but 100 mg to 1 g is more preferable.
[0024]
Thus, according to the present invention, despite the intake of salt, the increase in blood pressure is suppressed, and a salt-containing food or drink that can further suppress cardiac hypertrophy, for example, salt, miso, soy sauce or salt processed using these. Includes liquid seasonings (such as grilled meat sauce, ponzu soy sauce, and sauces), dried plums, pickles (such as pickled vegetables, takuan, etc.), luxury items (such as dried fish), salted fish, dairy products (such as butter), mayonnaise, and meat and meat products (such as sausage) ), Confectionery, nuts and sports drinks.
[0025]
Hereinafter, the effects of the present invention will be specifically described with reference to experimental examples.
Experimental example 1
[0026]
Experimental example 1
(Experimental example for confirming the effect of suppressing hypertensive cardiac hypertrophy)
The test was conducted by dividing 48 5-week-old, spontaneously hypertensive rats (hereinafter, SHR rats) into 8 groups of 6 rats each.
In the first group (control group), 6% (W / W, hereinafter% is by W / W unless otherwise specified) salt (NaCl) -supplemented feed (manufactured by Oriental Yeast Co., Ltd., mouse and rat feed) MF powder feed "to which 6% salt was added).
The second group (Comparative Example 1 section) was fed a 6% salt (NaCl) -added feed supplemented with 1% KCl.
The third group (Comparative Example 2 section) was fed a diet in which nicotianamine (hereinafter abbreviated as NF) was further added at a rate of 0.1% to a diet supplemented with 6% salt (NaCl).
The fourth group (comparative section 3) was fed a 6% salt (NaCl) supplemented feed supplemented with 0.2% isoflavone aglycone (hereinafter abbreviated as IF).
The fifth group (comparative section 4) was fed a 6% salt (NaCl) supplemented feed supplemented with 0.1% γ-aminobutyric acid (hereinafter abbreviated as GABA).
Group 6 (section 1 of the present invention) was fed with a 6% salt (NaCl) supplemented feed supplemented with 1% KCl and 0.1% nicotianamine.
The seventh group (section 2 of the present invention) was provided with data obtained by adding 1% KCl and 0.2% isoflavone aglycone to a feed supplemented with 6% salt (NaCl).
The eighth group (section 3 of the present invention) was provided with data obtained by adding KCl at a ratio of 1% and γ-aminobutyric acid at a ratio of 0.2% to a feed supplemented with 6% salt (NaCl).
At the end of the three-week test period, the rats were weighed, anesthetized with Nembutal, exsanguinated and killed, and the heart was excised and its wet weight was measured to calculate the heart weight per 100 g of body weight. Further, a relative value was calculated assuming that the heart weight per 100 g body weight in Comparative Example 1 was 100. Table 1 shows the results.
[0027]
From the results shown in Table 1, the salt-containing food administration group to which the substance having a blood pressure lowering action (nicotianamine) was added (Comparative Example 2) and the salt-containing food to which the substance having a blood pressure lowering action (isoflavone aglycone) was added (Comparative Example) 3) and the salt-containing food administration group to which the substance having a blood pressure lowering action (γ-aminobutyric acid) was added (Comparative Example 3) were compared with the salt-containing food-administering group not containing the substance having a blood pressure lowering action (control group). Therefore, since the heart wet weight hardly changes, these substances having a blood pressure lowering effect are expected to suppress the increase in blood pressure due to the presence of the substance having a blood pressure lowering effect when added to food containing salt. Although it is possible, it is understood that the effect of suppressing cardiac hypertrophy cannot be expected.
On the other hand, a salt-containing food administration group in which a substance having a blood pressure lowering action (nicotianamine) and potassium chloride are added in combination (the present invention 1), and a salt-containing food in which a substance having a blood pressure lowering action (isoflavone aglycone) and potassium chloride are added together The food-administered group (the present invention 2) and the salt-containing food-administered group to which a substance having a blood pressure lowering action (γ-aminobutyric acid) and potassium chloride are added in combination (the present invention 3) are the salt containing no substance having a blood pressure lowering action. It was found that the heart wet weight was reduced by 5 to 7% as compared to the food-containing administration group (control group) or the saline-containing food administration group to which potassium chloride was added (Comparative Example 1). From this, it is understood that according to the present invention, a salt-containing food that can suppress an increase in blood pressure and prevent cardiac hypertrophy can be obtained.
[0028]
【Example】
Hereinafter, the present invention will be described more specifically with reference to examples.
[0030]
Example 1
(Salty composition)
60 g of common salt, 30 g of potassium chloride and 10 g of γ-aminobutyric acid were uniformly mixed to obtain a salty composition of the present invention.
[0031]
Example 2
(Soy sauce)
1.7 g of nicotianamine and 1.5 g of potassium chloride were added and dissolved in 100 ml of hot soy sauce (salt 15% W / W) obtained according to a usual method for producing soy sauce to obtain a soy sauce of the present invention.
[0032]
Example 3
(Soy sauce)
3.4 g of isoflavone aglycone and 1.5 g of potassium chloride were added and dissolved in 100 ml of hot soy sauce (salt 15% W / W) obtained according to a usual method for producing soy sauce to obtain a soy sauce of the present invention.
[0033]
Example 4
(miso)
3.4 g of γ-aminobutyric acid and 1.2 g of potassium chloride were added and dissolved in 100 g of red miso (11% w / w salt) obtained according to the usual method for producing miso to obtain the miso of the present invention.
[0034]
【The invention's effect】
ADVANTAGE OF THE INVENTION According to this invention, when a salt-containing food or drink is ingested, the salt-containing food or drink which can suppress a rise in blood pressure and prevent cardiac hypertrophy can be obtained.
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003089773A JP2004290129A (en) | 2003-03-28 | 2003-03-28 | Common salt-containing food or beverage |
| PCT/JP2004/003421 WO2004086880A1 (en) | 2003-03-28 | 2004-03-15 | Sodium chloride-containing foods and drinks |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003089773A JP2004290129A (en) | 2003-03-28 | 2003-03-28 | Common salt-containing food or beverage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004290129A true JP2004290129A (en) | 2004-10-21 |
Family
ID=33127250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003089773A Pending JP2004290129A (en) | 2003-03-28 | 2003-03-28 | Common salt-containing food or beverage |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2004290129A (en) |
| WO (1) | WO2004086880A1 (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006033205A1 (en) * | 2004-09-22 | 2006-03-30 | Kikkoman Corporation | Low-salt soy sauce |
| JP2006136262A (en) * | 2004-11-12 | 2006-06-01 | Kao Corp | Liquid seasoning |
| JP2006166906A (en) * | 2004-11-19 | 2006-06-29 | Kao Corp | Liquid seasoning |
| JP2006166752A (en) * | 2004-12-14 | 2006-06-29 | Kao Corp | Liquid seasoning |
| JP2006246840A (en) * | 2005-03-14 | 2006-09-21 | Yamamori Kk | Method for producing functional food |
| WO2006114918A1 (en) * | 2005-04-22 | 2006-11-02 | Yaizu Suisankagaku Industry Co., Ltd. | Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride produced by the process |
| JP2006314316A (en) * | 2005-04-15 | 2006-11-24 | Kao Corp | Method for producing liquid seasoning |
| JP2006325578A (en) * | 2005-04-27 | 2006-12-07 | Kao Corp | Method for producing liquid seasoning |
| JP2007089557A (en) * | 2004-11-12 | 2007-04-12 | Kao Corp | Liquid seasoning |
| JP2007129920A (en) * | 2005-11-08 | 2007-05-31 | Manac Inc | Salt composition and method for producing the same |
| JP2007222117A (en) * | 2006-02-27 | 2007-09-06 | Kao Corp | Container liquid seasoning |
| JP2007267724A (en) * | 2006-03-06 | 2007-10-18 | Kao Corp | Powder seasoning |
| JP2007300821A (en) * | 2006-05-09 | 2007-11-22 | Kao Corp | Powder seasoning |
| US7666409B2 (en) | 2004-11-16 | 2010-02-23 | Kao Corporation | Low salt liquid seasoning with antihypertensive activity |
| US7727524B2 (en) | 2004-11-12 | 2010-06-01 | Kao Corporation | Low sodium liquid seasoning with anti-hypertensive activity |
| JP2011036269A (en) * | 2010-11-25 | 2011-02-24 | Kao Corp | Powder seasoning |
| JP2011120603A (en) * | 2005-04-27 | 2011-06-23 | Kao Corp | Method for producing liquid seasoning |
| WO2011078324A1 (en) | 2009-12-25 | 2011-06-30 | キッコーマン株式会社 | Soy sauce having hypotensive effect and method for producing same |
| US8053014B2 (en) | 2005-11-14 | 2011-11-08 | Kao Corporation | Liquid seasoning |
| US8399034B2 (en) | 2008-01-31 | 2013-03-19 | Kao Corporation | Miso |
| JPWO2011089764A1 (en) * | 2010-01-20 | 2013-05-20 | 焼津水産化学工業株式会社 | Taste improving agent for potassium chloride-containing food and drink and method for producing potassium chloride-containing food and drink |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06345664A (en) * | 1993-06-11 | 1994-12-20 | Takako Tomita | New composition for suppressing elevation of blood pressure |
| EP0919137B1 (en) * | 1996-07-15 | 2003-09-17 | Fujisawa Pharmaceutical Co., Ltd. | Functional sodium chloride compositions |
| JP4246407B2 (en) * | 2001-04-27 | 2009-04-02 | キッセイ薬品工業株式会社 | Liquid seasoning |
-
2003
- 2003-03-28 JP JP2003089773A patent/JP2004290129A/en active Pending
-
2004
- 2004-03-15 WO PCT/JP2004/003421 patent/WO2004086880A1/en active Application Filing
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006033205A1 (en) * | 2004-09-22 | 2006-03-30 | Kikkoman Corporation | Low-salt soy sauce |
| JP2006087328A (en) * | 2004-09-22 | 2006-04-06 | Kikkoman Corp | Low-salt soy sauce |
| US7718209B2 (en) | 2004-09-22 | 2010-05-18 | Kikkoman Corporation | Low-salt soy sauce |
| JP2006136262A (en) * | 2004-11-12 | 2006-06-01 | Kao Corp | Liquid seasoning |
| KR101243537B1 (en) * | 2004-11-12 | 2013-03-20 | 카오카부시키가이샤 | Liquid seasoning |
| US7887868B2 (en) | 2004-11-12 | 2011-02-15 | Kao Corporation | Liquid seasoning |
| US7727524B2 (en) | 2004-11-12 | 2010-06-01 | Kao Corporation | Low sodium liquid seasoning with anti-hypertensive activity |
| JP2007089557A (en) * | 2004-11-12 | 2007-04-12 | Kao Corp | Liquid seasoning |
| US8092795B2 (en) | 2004-11-16 | 2012-01-10 | Kao Corporation | Liquid seasoning |
| US7666409B2 (en) | 2004-11-16 | 2010-02-23 | Kao Corporation | Low salt liquid seasoning with antihypertensive activity |
| JP2006166906A (en) * | 2004-11-19 | 2006-06-29 | Kao Corp | Liquid seasoning |
| JP2006166752A (en) * | 2004-12-14 | 2006-06-29 | Kao Corp | Liquid seasoning |
| JP2006246840A (en) * | 2005-03-14 | 2006-09-21 | Yamamori Kk | Method for producing functional food |
| JP2006314316A (en) * | 2005-04-15 | 2006-11-24 | Kao Corp | Method for producing liquid seasoning |
| JP5680815B2 (en) * | 2005-04-22 | 2015-03-04 | 焼津水産化学工業株式会社 | Method for producing potassium chloride-containing food and drink, and potassium chloride-containing food and drink obtained by the production method |
| WO2006114918A1 (en) * | 2005-04-22 | 2006-11-02 | Yaizu Suisankagaku Industry Co., Ltd. | Taste improving agent for food and beverage containing potassium chloride, process for producing food and beverage containing potassium chloride and food and beverage containing potassium chloride produced by the process |
| JP2006325578A (en) * | 2005-04-27 | 2006-12-07 | Kao Corp | Method for producing liquid seasoning |
| JP2011120603A (en) * | 2005-04-27 | 2011-06-23 | Kao Corp | Method for producing liquid seasoning |
| JP2007129920A (en) * | 2005-11-08 | 2007-05-31 | Manac Inc | Salt composition and method for producing the same |
| US8053014B2 (en) | 2005-11-14 | 2011-11-08 | Kao Corporation | Liquid seasoning |
| JP2007222117A (en) * | 2006-02-27 | 2007-09-06 | Kao Corp | Container liquid seasoning |
| JP2007267724A (en) * | 2006-03-06 | 2007-10-18 | Kao Corp | Powder seasoning |
| JP2007300821A (en) * | 2006-05-09 | 2007-11-22 | Kao Corp | Powder seasoning |
| US8399034B2 (en) | 2008-01-31 | 2013-03-19 | Kao Corporation | Miso |
| WO2011078324A1 (en) | 2009-12-25 | 2011-06-30 | キッコーマン株式会社 | Soy sauce having hypotensive effect and method for producing same |
| JPWO2011089764A1 (en) * | 2010-01-20 | 2013-05-20 | 焼津水産化学工業株式会社 | Taste improving agent for potassium chloride-containing food and drink and method for producing potassium chloride-containing food and drink |
| JP2011036269A (en) * | 2010-11-25 | 2011-02-24 | Kao Corp | Powder seasoning |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004086880A1 (en) | 2004-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004290129A (en) | Common salt-containing food or beverage | |
| JP6449416B2 (en) | Flavor improver | |
| JP5688687B2 (en) | Use for adding rich taste to peptides | |
| CN101677621B (en) | Low-fat food | |
| KR101410710B1 (en) | Kokumi-imparting agent | |
| TWI364259B (en) | Brewing soy sauce with few smell of soy sauce and the preparation method thereof | |
| KR101452012B1 (en) | A taste enhancing agent such as a salty taste, and a salty taste enhancing method such as a salty taste of a food or drink | |
| CN102753041B (en) | Dense taste imparting agent | |
| JP2008073007A (en) | Vinegar corner control method | |
| CN1719987A (en) | Beverages containing amino acids and method for reducing the bitterness of amino acids | |
| WO2006013997A1 (en) | Seasoning composition, seasoning material and process for producing food therewith | |
| JP4319968B2 (en) | Liquid seasoning | |
| US20160374380A1 (en) | Salty taste enhancer | |
| JP2010011807A (en) | Salty taste enhancer containing magnesium glutamate | |
| JP2006136262A (en) | Liquid seasoning | |
| JP4542884B2 (en) | Liquid seasoning | |
| JP4319969B2 (en) | Liquid seasoning | |
| JP6113098B2 (en) | Salt enhancer | |
| JP6352190B2 (en) | Salty taste enhancer, method for producing the same, and salty taste enhancing method | |
| JP2020074702A (en) | First taste enhancing agent | |
| WO2014061705A1 (en) | Food or drink with enhanced salty taste and/or umami and manufacturing method therefor, salty taste and/or umami-enhancing composition for food or drink, and method for enhancing salty taste and/or umami of food or drink | |
| HK1206943B (en) | Flavor improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050714 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080902 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081029 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20081125 |